Exelixis | EXEL - Market Capitalization

Stock Price
41.09
Daily Change
-0.15 -0.36%
Monthly
-6.78%
Yearly
10.99%
Q1 Forecast
39.99

Exelixis reported $11.79B in Market Capitalization this March of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 4.52B 919M Dec/2025
Agios Pharmaceuticals USD 1.59B 745M Dec/2025
Akebia Therapeutics USD 502M 75M Mar/2025
Amgen USD 176.25B 24.32B Dec/2025
AstraZeneca USD 288.15B 55.08B Dec/2025
Bayer EUR 36.89B 535.42M Mar/2026
BioMarin Pharmaceutical USD 11.76B 348M Mar/2026
Bristol-Myers Squibb USD 109.81B 18.01B Dec/2025
Cytokinetics USD 7.77B 1.19B Dec/2025
Eisai JPY 1.31T 140.95B Dec/2025
Eli Lilly USD 1.02T 293.84B Dec/2025
Esperion Therapeutics USD 475M 410M Mar/2026
Exelixis USD 11.75B 959M Dec/2025
Genmab DKK 80.88B 7.82B Jun/2025
Glaxosmithkline GBP 86.88B 7.29B Sep/2025
Incyte USD 19.39B 2.83B Dec/2025
Ionis Pharmaceuticals USD 12.81B 2.39B Dec/2025
MacroGenics USD 106M 29M Sep/2025
Merck USD 261.26B 51.62B Dec/2025
Neurocrine Biosciences USD 14.14B 218M Dec/2025
Novartis USD 265.66B 9.48B Sep/2025
Pfizer USD 141.57B 6.48B Dec/2025
Sanofi EUR 117.34B 2.45B Dec/2025
Takeda JPY 7.64T 774.9B Dec/2025
Ultragenyx Pharmaceutical USD 2.22B 680M Dec/2025
Xencor USD 1.09B 256M Dec/2025